Update on a patient with superficial siderosis on deferiprone

American Journal of Neuroradiology

Volumn 33, Issue 6, 2012, Pages

  Levy, M ^a   Llinas, R H ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DEFERIPRONE;

CHELATION THERAPY; CLINICAL TRIAL (TOPIC); DRUG EFFICACY; FOLLOW UP; HUMAN; LETTER; NERVE DEGENERATION; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOME ASSESSMENT; SIDEROSIS; SUPERFICIAL SIDEROSIS;

ADULT; BRAIN DISEASES; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; SIDEROSIS; TREATMENT OUTCOME;

EID: 84862550409     PISSN: 01956108     EISSN: 1936959X     Source Type: Journal    
DOI: 10.3174/ajnr.A3186     Document Type: Letter

References (4)

1. Levy M, Turtzo C, Llinas RH. Superficial siderosis: a case report and review of the literature. Nat Clin Pract Neurol 2007;3:54-58 (Pubitemid 46056034)
2. Levy M, Llinas RH. Deferiprone reduces hemosiderin deposits in the brain of a patient with superficial siderosis. AJNR Am J Neuroradiol 2011;32:E1-2
3. Levy M, Llinas RH. Pilot safety trial of deferiprone in 10 subjects with superficial siderosis. Stroke 2012;43:120-24
4. Fredenburg AM, Sethi RK, Allen DD, et al. The pharmacokinetics and bloodbrain barrier permeation of the chelators 1,2 dimethly-, 1,2 diethyl-, and 1-[ethan-1′ol]-2-methyl-3-hydroxypyridin-4-one in the rat. Toxicology 1996;108:191-99